"Instead of daily pills or intermittent injections over decades to lower bad cholesterol, this study reveals the potential for a new treatment option - a single-course therapy that may lead to deep [LDL] lowering for decades," said Andrew Bellinger, chief scientific officer at Verve Therapeutics.
In the clinical trial, 10 participants received an intravenous infusion of the base editor targeting PCSK9. The results of this study suggest that the therapy has the potential to revolutionize FH treatment.
[
add
]
[
|
|
...
]